ECSP23090260A - Compuestos indol sustituidos y métodos de uso de los mismos - Google Patents
Compuestos indol sustituidos y métodos de uso de los mismosInfo
- Publication number
- ECSP23090260A ECSP23090260A ECSENADI202390260A ECDI202390260A ECSP23090260A EC SP23090260 A ECSP23090260 A EC SP23090260A EC SENADI202390260 A ECSENADI202390260 A EC SENADI202390260A EC DI202390260 A ECDI202390260 A EC DI202390260A EC SP23090260 A ECSP23090260 A EC SP23090260A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- methods
- substituted indol
- inhibitors
- complement
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 102000003712 Complement factor B Human genes 0.000 abstract 1
- 102100034622 Complement factor B Human genes 0.000 abstract 1
- 108090000056 Complement factor B Proteins 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 230000004154 complement system Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 150000002475 indoles Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
La presente invención proporciona compuestos indol sustituidos. En ciertas formas de realización, los compuestos son inhibidores de la vía alternativa del sistema del complemento y, en particular, inhibidores del factor B del complemento. (CFB). Además se proporcionan composiciones que comprenden los compuestos y métodos de uso de los mismos. Los compuestos proporcionados son útiles en el tratamiento, prevención o mejora de una enfermedad, afección o trastorno mediante la inhibición de la vía alternativa del complemento.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163196339P | 2021-06-03 | 2021-06-03 | |
US202163290019P | 2021-12-15 | 2021-12-15 | |
US202263346120P | 2022-05-26 | 2022-05-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP23090260A true ECSP23090260A (es) | 2024-02-29 |
Family
ID=84323595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202390260A ECSP23090260A (es) | 2021-06-03 | 2023-11-30 | Compuestos indol sustituidos y métodos de uso de los mismos |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP4346812A2 (es) |
JP (1) | JP2024521878A (es) |
KR (1) | KR20240017004A (es) |
AU (1) | AU2022283903A1 (es) |
BR (1) | BR112023025235A2 (es) |
CA (1) | CA3222144A1 (es) |
CO (1) | CO2023016557A2 (es) |
CR (1) | CR20230564A (es) |
DO (1) | DOP2023000263A (es) |
EC (1) | ECSP23090260A (es) |
IL (1) | IL308835A (es) |
WO (1) | WO2022256586A2 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3236104A1 (en) * | 2021-10-27 | 2023-05-04 | Hugh Y. Zhu | Piperidinyl indole derivatives, preparation methods and medicinal uses thereof |
WO2023139534A1 (en) * | 2022-01-24 | 2023-07-27 | Novartis Ag | Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof |
WO2023237012A1 (zh) * | 2022-06-07 | 2023-12-14 | 正大天晴药业集团股份有限公司 | 双环取代的芳香羧酸类氘代化合物 |
WO2023246677A1 (zh) * | 2022-06-20 | 2023-12-28 | 深圳信立泰药业股份有限公司 | 一种吲哚-苯基哌啶化合物及其制备方法与应用 |
WO2023246870A1 (zh) * | 2022-06-23 | 2023-12-28 | 上海济煜医药科技有限公司 | 吲哚化合物的制备、应用及用途 |
WO2024049977A1 (en) * | 2022-08-31 | 2024-03-07 | Chinook Therapeutics, Inc. | Substituted indole compounds and methods of use thereof |
WO2024051849A1 (en) * | 2022-09-10 | 2024-03-14 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | 2-substituted piperidine derivatives, preparation methods and medicinal uses thereof |
WO2024104292A1 (en) * | 2022-11-14 | 2024-05-23 | Novartis Pharma Ag | Solid forms of complement factor b inhibitors |
WO2024114677A1 (zh) * | 2022-11-29 | 2024-06-06 | 上海济煜医药科技有限公司 | 苯并螺环吲哚化合物的制备、应用及用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104619698B (zh) * | 2012-06-28 | 2016-08-31 | 诺华股份有限公司 | 吡咯烷衍生物及其作为补体途径调节剂的用途 |
JO3425B1 (ar) * | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
RU2018145364A (ru) * | 2016-06-27 | 2020-07-28 | Ачиллион Фармасьютикалс, Инк. | Хиназолиновые и индольные соединения для лечения медицинских нарушений |
EP4282486A3 (en) * | 2020-08-07 | 2024-03-06 | Shanghai Meiyue Biotech Development Co., Ltd. | Complement factor b inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof |
-
2022
- 2022-06-03 IL IL308835A patent/IL308835A/en unknown
- 2022-06-03 AU AU2022283903A patent/AU2022283903A1/en active Pending
- 2022-06-03 KR KR1020237045081A patent/KR20240017004A/ko unknown
- 2022-06-03 CR CR20230564A patent/CR20230564A/es unknown
- 2022-06-03 WO PCT/US2022/032042 patent/WO2022256586A2/en active Application Filing
- 2022-06-03 EP EP22816892.8A patent/EP4346812A2/en active Pending
- 2022-06-03 JP JP2023574119A patent/JP2024521878A/ja active Pending
- 2022-06-03 CA CA3222144A patent/CA3222144A1/en active Pending
- 2022-06-03 BR BR112023025235A patent/BR112023025235A2/pt unknown
-
2023
- 2023-11-30 CO CONC2023/0016557A patent/CO2023016557A2/es unknown
- 2023-11-30 DO DO2023000263A patent/DOP2023000263A/es unknown
- 2023-11-30 EC ECSENADI202390260A patent/ECSP23090260A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3222144A1 (en) | 2022-12-08 |
IL308835A (en) | 2024-01-01 |
WO2022256586A3 (en) | 2023-01-12 |
DOP2023000263A (es) | 2024-02-29 |
EP4346812A2 (en) | 2024-04-10 |
CO2023016557A2 (es) | 2024-02-26 |
WO2022256586A2 (en) | 2022-12-08 |
AU2022283903A1 (en) | 2023-11-30 |
JP2024521878A (ja) | 2024-06-04 |
KR20240017004A (ko) | 2024-02-06 |
BR112023025235A2 (pt) | 2024-02-27 |
CR20230564A (es) | 2024-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2023000263A (es) | Compuestos indol sustituidos y métodos de uso de los mismos | |
UY38403A (es) | Moduladores de la alfa-1 antitripsina | |
CO2022015638A2 (es) | Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso | |
CR20180495A (es) | Deribados de indol sustituidos como inhibidores de replicación viral del dengue | |
NI201800040A (es) | Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue | |
CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
NI201800039A (es) | Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue | |
CL2017001822A1 (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
CL2017000742A1 (es) | Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue | |
PA8675701A1 (es) | Nuevos derivados del fluoreno, composiciones que los contienen y su utilización | |
CR10277A (es) | Pirazolquinolonas como potentes inhibidores de parp | |
GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
CO2018009563A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
ECSP19051352A (es) | Inhibidores selectivos de jak1 | |
CL2021001753A1 (es) | Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253). | |
CL2022002695A1 (es) | Inhibidores de rip1k | |
CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
CO2022008662A2 (es) | Degradadores de smarca y usos de los mismos | |
CL2020003380A1 (es) | Compuestos que aumentan la actividad del proteosoma. | |
CR20220199A (es) | Inhibidores del factor d del complemento para administración oral | |
CU20220025A7 (es) | Inihibidores del factor d del complemento para administración oral | |
DOP2010000197A (es) | Derivados de oxindol sustituidos y uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina | |
CO2023015732A2 (es) | Moduladores de trex1 | |
CL2017003350A1 (es) | Composiciones farmacéuticas sólidas para el tratamiento del vhc | |
CL2022003206A1 (es) | Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501) |